• Mutation; HGNC; HGNC:882; ATR; Unexplicit; Ex29-34del; Zygosity=Heterozygous (PubMed=16827800).
  

PubMed=8152260
Gong J.-H., Maki G., Klingemann H.-G.
Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells.
Leukemia 8:652-658(1994)

PubMed=9118301
Klingemann H.-G., Wong E., Maki G.
A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.
Biol. Blood Marrow Transplant. 2:68-75(1996)

PubMed=9573023; DOI=10.1182/blood.V91.10.3850
Nagashima S., Mailliard R., Kashii Y., Reichert T.E., Herberman R.B., Robbins P., Whiteside T.L.
Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo.
Blood 91:3850-3861(1998)

PubMed=10365666; DOI=10.1089/10430349950018030
Tam Y.K., Maki G., Miyagawa B., Hennemann B., Tonn T., Klingemann H.-G.
Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy.
Hum. Gene Ther. 10:1359-1373(1999)

PubMed=10803505; DOI=10.1038/sj.leu.2401778
Drexler H.G., Matsuo Y.
Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma.
Leukemia 14:777-782(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001)

PubMed=11454312; DOI=10.1089/152581601750288975
Maki G., Klingemann H.-G., Martinson J.A., Tam Y.K.
Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92.
J. Hematother. Stem Cell Res. 10:369-383(2001)

PubMed=12850795; DOI=10.1080/14653240310001523
Tam Y.K., Martinson J.A., Doligosa K., Klingemann H.-G.
Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.
Cytotherapy 5:259-272(2003)

PubMed=16827800; DOI=10.1111/j.1349-7006.2006.00226.x; PMCID=PMC11159954
Liu A., Takakuwa T., Luo W.-J., Fujita S., Aozasa K.
Alterations in ATR in nasal NK/T-cell lymphoma and chronic active Epstein-Barr virus infection.
Cancer Sci. 97:605-610(2006)

PubMed=18424763; DOI=10.4049/jimmunol.180.9.6392; PMCID=PMC2810560
Binyamin L., Alpaugh R.K., Hughes T.L., Lutz C.T., Campbell K.S., Weiner L.M.
Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.
J. Immunol. 180:6392-6401(2008)

PubMed=19194464; DOI=10.1038/leu.2009.3
Iqbal J., Kucuk C., Deleeuw R.J., Srivastava G., Tam W., Geng H.-M., Klinkebiel D.L., Christman J.K., Patel K.N., Cao K., Shen L., Dybkaer K., Tsui I.F.L., Ali H.H., Shimizu N., Au W.Y., Lam W.L., Chan W.-C.
Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies.
Leukemia 23:1139-1151(2009)

PubMed=20454443; DOI=10.1155/2010/904767; PMCID=PMC2861168
Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010)

PubMed=21052088; DOI=10.1038/leu.2010.255
Iqbal J., Weisenburger D.D., Chowdhury A., Tsai M.-Y., Srivastava G., Greiner T.C., Kucuk C., Deffenbacher K.E., Vose J.M., Smith L., Au W.Y., Nakamura S., Seto M., Delabie J., Berger F., Loong F., Ko Y.-H., Sng I., Liu X., Loughran T.P. Jr., Armitage J.O., Chan W.-C.
International Peripheral T-cell Lymphoma Project
Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro.
Leukemia 25:348-358(2011)

PubMed=21570725; DOI=10.1016/j.molimm.2011.04.010
Schnueriger A., Grau R., Sondermann P., Schreitmueller T., Marti S., Zocher M.
Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies.
Mol. Immunol. 48:1512-1517(2011)

PubMed=25586472; DOI=10.1038/ncomms7025; PMCID=PMC7743911
Kucuk C., Jiang B., Hu X.-Z., Zhang W.-Y., Chan J.K.C., Xiao W.-M., Lack N., Alkan C., Williams J.C., Avery K.N., Kavak P., Scuto A., Sen E., Gaulard P., Staudt L.M., Iqbal J., Zhang W.-W., Cornish A., Gong Q., Yang Q.-P., Sun H., d'Amore F.A., Leppa S., Liu W.-P., Fu K., de Leval L., McKeithan T.W., Chan W.-C.
Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells.
Nat. Commun. 6:6025.1-6025.12(2015)

PubMed=26559813; DOI=10.1007/s00262-015-1761-x; PMCID=PMC11029582
Suck G., Odendahl M., Nowakowska P., Seidl C., Wels W.S., Klingemann H.-G., Tonn T.
NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.
Cancer Immunol. Immunother. 65:485-492(2016)

PubMed=30054012; DOI=10.1016/j.molimm.2018.07.015; PMCID=PMC6345623
Gunesch J.T., Angelo L.S., Mahapatra S., Deering R.P., Kowalko J.E., Sleiman P., Tobias J.W., Monaco-Shawver L., Orange J.S., Mace E.M.
Genome-wide analyses and functional profiling of human NK cell lines.
Mol. Immunol. 115:64-75(2019)

PubMed=31126350; DOI=10.1186/s40425-019-0612-2; PMCID=PMC6534912
Yang H.G., Kang M.C., Kim T.Y., Hwang I., Jin H.T., Sung Y.C., Eom K.-S., Kim S.W.
Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy.
J. Immunother. Cancer 7:138.1-138.17(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x; PMCID=PMC6547646
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)

PubMed=34349345; DOI=10.1007/s10616-021-00476-1; PMCID=PMC8319282
Zhao H., Zhou Z.-L., Li G.-M., Liu G., Lin S.-Y., Chen W., Xiong S.
An NK cell line (NK92-41BB) expressing high levels of granzyme is engineered to express the high affinity chimeric genes CD16/CAR.
Cytotechnology 73:539-553(2021)

PubMed=36610812; DOI=10.1016/j.jcyt.2022.12.003
Klingemann H.-G.
The NK-92 cell line -- 30 years later: its impact on natural killer cell research and treatment of cancer.
Cytotherapy 25:451-457(2023)